Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. Eichler, H., Adams, R., Andreassen, E., Arlett, P., Van de Casteele, M., Chapman, S., . . . Wenzl, M. (2021). International Journal of Technology Assessment in Health Care, 37(1), E83. doi:10.1017/S026646232100057X
The Utility of a Rapid Review Evaluation Process to a National HTA Agency. Varley A, Tilson L, Fogarty E, McCullagh L, Barry M. PharmacoEconomics 2021. DOI: 10.1007/s40273-021-01093-8
Absence of evidence or evidence of absence – a review of the evidence for hydroxychloroquine as a potential candidate for prophylaxis against COVID-19. Cara Usher, Lea Trela-Larsen, Emer Fogarty, Aisling O’Leary, Stephen Capper, Ellen P O’Sullivan, Caitriona NiChoitir, Cathal Walsh, Michael Barry, Roisín Adams. Ann Public Health Reports 2021;5(1):160-165. DOI: 10.36959/856/513
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2. McConnell D, Hickey C, Bargary N, Trela-Larsen L, Walsh C, Barry M, Adams R. Int. J. Environ. Res. Public Health 2021, 18, 4640. https://doi.org/10.3390/ijerph18094640
Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. Kennedy C, McCullagh L, Adams R, Trela-Larsen L, Tilson L, Barry M, Value in Health, 2021, ISSN 1098-3015, https://doi.org/10.1016/j.jval.2021.03.012. (https://www.sciencedirect.com/science/article/pii/S1098301521002096)
Integrating clinical pharmacists within general practice: protocol for a pilot cluster randomised controlled trial. Croke A, Moriarty F, Boland F, McCullagh L, Cardwell, K, Smith , SM, Clynee B. BMJ Open 2021;11:e041541. doi:10.1136/ bmjopen-2020-041541
